
Avalo Therapeutics (AVTX) Stock Forecast & Price Target
Avalo Therapeutics (AVTX) Analyst Ratings
Bulls say
Avalo Therapeutics has demonstrated significant pre-market momentum, with a notable increase of approximately 22%, driven by growing investor confidence in the company's anti-IL-1B monoclonal antibody, AVTX-009, particularly regarding its potential applications in inflammatory diseases. The anticipation surrounding the forthcoming LOTUS data readout underlines the market's increasing recognition of AVTX-009's efficacy in treating hidradenitis suppurativa (HS), suggesting a favorable environment for potential market expansion. Additionally, the broader therapeutic landscape for HS appears to be evolving, creating opportunities for Avalo Therapeutics as access to more effective and durable therapies grows.
Bears say
Avalo Therapeutics's stock outlook is negatively influenced by concerns regarding safety, as the reported incidence of neutropenia in 4.3% of cases, including instances of Grade 3 decreases in neutrophil counts, may raise regulatory scrutiny and impact the medication's acceptance in the market. Additionally, the presence of target distraction due to lutikizumab's binding to both IL-1β and IL-1α could potentially hinder its effectiveness, complicating its therapeutic profile. Furthermore, the historical low rate of diagnosis and treatment for the conditions being targeted suggests a limited market opportunity, potentially constraining future revenue growth for Avalo's pipeline products.
This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Avalo Therapeutics (AVTX) Analyst Forecast & Price Prediction
Start investing in Avalo Therapeutics (AVTX)
Order type
Buy in
Order amount
Est. shares
0 shares